Illumina, Inc. ILMN | NASDAQ
Next Earnings: Aug 04, 2025
Company Overview:
10 Year ILMN Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
ILMN Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for ILMN
Based on past 10-year performance, here are ILMN growth metrics:
Share price CAGR of -7.65%
Dividend CAGR of +0%
Using ILMN CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| ILMN (DRIP) | ILMN - No DRIP | |
|---|---|---|
| Current Price | $99.54 | $99.54 |
| Start Shares | 100.46 | 100.46 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 100.46 | 100.46 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $48.62 | $99.54 |
| Total Dividends | $0 | $0 |
| Final Value | $4,884 | $10,000 |
NOTE: Above numbers are our estimate based on ILMN's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Illumina, Inc. (ILMN) had its IPO on 2000-07-28, and is trader on NASDAQ stock exchange.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
ILMN website: https://www.illumina.com
